Quazepam: Hypnotic Efficacy and Side Effects

  title={Quazepam: Hypnotic Efficacy and Side Effects},
  author={Anthony Kales},
  journal={Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy},
  • A. Kales
  • Published 2 January 1990
  • Medicine, Psychology
  • Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy
Quazepam is a benzodiazepine hypnotic that can be useful in the adjunctive pharmacologic treatment of insomnia. It is slowly eliminated due to the long elimination half‐lives of the parent compound and its two active metabolites, 2‐oxoqua‐zepam and N‐desalkyl‐2‐oxoquazepam. This drug is recommended in doses of 15 mg for adults and 7.5 mg for geriatric patients. Sleep laboratory studies and clinical trials have shown that the 15 mg dose is quite efficacious for inducing and maintaining sleep not… 
Hypnotic effects of low doses of quazepam in older insomniacs.
Analyses of plasma concentrations of quzepam and its metabolites suggested the continued drug effects on sleep during recovery are due to the metabolite desalkylflurazepam, and the safety evaluation done by means of adverse drug event assessments and postsleep questionnaires was minimal.
Pharmacokinetic Determinants of the Clinical Effects of Benzodiazepine Agonist Hypnotics
O Ongoing pharmaceutical research has the objective of developing drug delivery innovations that can optimize hypnotic drug action by regulation of release and systemic exposure to short half-life BZ agonists.
Rebound insomnia and newer hypnotics
  • M. Lader
  • Psychology, Medicine
  • 2005
Present evidence, while limited, is consistent with claims of less rebound potential than older benzodiazepine hypnotics of equivalent duration of action, but further rigorous studies are essential before these claims can be totally accepted.
Sedatives and Hypnotics
This chapter will discuss the uses of hypnotics and sedatives for the treatment of insomnia and outline appropriate management strategies for effective treatment outcomes.
Drug interaction between St John's Wort and quazepam.
It is suggested that SJW decreases plasma quazepam concentrations, probably by enhancing CYP3A4 activity, but does not influence the pharmacodynamic effects of the drug.
Insomnia Management and Hypnotic Benzodiazepine Therapeutics
How common insomnia is and how important it is for health professionals to understand hypnotic drug use are indicated are indicated.
Time effects of food intake on the pharmacokinetics and pharmacodynamics of quazepam.
The dosing of quazepam after a long period of ordinary fasting might reduce its efficacy because a 3 h interval between the timing of the evening meal and bedtime administration of hypnotics is regarded as normal in daily life.
Comparison of hangover effects among triazolam, flunitrazepam and quazepam in healthy subjects: A preliminary report
Subjective hangover effects assessed by SSS and SEQ in the morning were prominent for flunitrazepam and quazepam relative to triazolam, whereas objective indices such as MSLT or activity counts obtained in actigraphy indicated a marked hangover effect of quazEPam compared with the other two compounds restrictively in the afternoon, which were nearly in accordance with their pharmacokinetic profiles.
Beyond Benzodiazepines: Alternative Pharmacologic Agents for the Treatment of Insomnia
Novel nonbenzodiazepine hypnotics including zolpidem, zopiclone, and zaleplon, as well as nonprescription products such as valerian and melatonin, are reviewed in detail to provide an overview of the pharmacologic therapy of insomnia.
The Black Book of Psychotropic Dosing and Monitoring.
Since the last update of The Black Book in 2007, new psychotropics have expanded existing classes of drugs, while others have challenged the well-worn nomenclature of psychiatric agents.


Comparison of short and long half‐life benzodiazepine hypnotics: Triazolam and quazepam
The 0.25 mg dose of triazolam, which is being prescribed increasingly, has a profile of side effects that is similar to that of the 0.5 mg dose, and is associated with sleep and mood disturbances whereas quazepam exerted carryover effectiveness.
Sleep laboratory studies of hypnotic drugs: efficacy and withdrawal effects.
  • A. Kales, J. Kales
  • Psychology, Medicine
    Journal of clinical psychopharmacology
  • 1983
Rebound insomnia has not been noted following withdrawal of flurazepam; there is a carry-over effectiveness into the first and second nights of withdrawal, and any withdrawal sleep disturbance would be expected to be infrequent, delayed in appearance, and mild in degree.
Effectiveness of hypnotic drugs with prolonged use: Flurazepam and pentobarbital
Pentobarbital was found to be effective in inducing and maintaining sleep only with short‐term drug administration, which strongly suggests that it is of limited value for insomniac patients who require nightly medication beyond short-term use.
Quazepam and flurazepam: Long‐term use and extended withdrawal
The data suggest that the optimal dose of quazepam is 15 mg, and some loss of effectiveness was noted during long‐term use of both doses of quzepam and, to a lesser extent, of flurazepams.
Quazepam and temazepam: Effects of short‐ and intermediate‐term use and withdrawal
Although temazepam was effective for maintaining sleep with short‐term use, there was rapid development of tolerance for this effect with intermediate‐ term use, and quazEPam had carryover effectiveness.
Dose—Response Studies of Lormetazepam: Efficacy, Side Effects, and Rebound Insomnia
There was less efficacy on the later drug nights, indicating a potential for the development of tolerance over a relatively short period of time, and following drug withdrawal, there was a dose‐related worsening of sleep above baseline levels (rebound insomnia).
Dose‐response studies of quazepam
The efficacy and comparatively less severe side effects of the 7.5‐and 15‐mg doses of quazepam suggest that these doses may be optimal when the drug is considered for the adjunctive treatment of insomnia.
Midazolam: dose-response studies of effectiveness and rebound insomnia.
There was less effectiveness on the last 3 drug nights, indicating a potential for the development of tolerance over a relatively short period of time and following withdrawal there was a marked dose-related worsening of sleep above baseline levels (rebound insomnia).
Hypnotic Efficacy of Triazolam: Sleep Laboratory Evaluation of Intermediate‐Term Effectiveness
The data indicate that triazolam is effective for short-term use, loses most of its effectiveness with intermediate- term use, and its withdrawal is followed by a significant sorsening of sleep.
Evaluation of the Short-Term Treatment of Insomnia in Out-Patients with 15 Milligrams of Quazepam
It is demonstrated that quazepam, in a 15 mg dose, is an effective, rapidly acting, oral hypnotic agent with a low incidence of adverse effects.